Clinical Trials Logo

Filter by:
NCT ID: NCT05481905 Withdrawn - Focal Epilepsy Clinical Trials

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

ENACT
Start date: September 2022
Phase: Phase 2
Study type: Interventional

The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to 4 antiseizure medications yet still experiencing seizures.

NCT ID: NCT05481814 Withdrawn - Clinical trials for Aortic Valve Stenosis

CPX in Paradoxical Low Flow Aortic Stenosis

Start date: September 30, 2017
Phase:
Study type: Observational

Severe aortic stenosis is a condition with poor life expectancy once it becomes symptomatic. There are no prospective studies illustrating the utility of cardiopulmonary stress (CPX) testing in diagnosing and prognosticating patients with paradoxically low gradient and low flow severe aortic stenosis. We aim to prospectively investigate the utility of CPX in this patient population with the hypothesis that utilizing CPX parameters would better identify higher risk patients warranting further evaluation and possibly intervention sooner.

NCT ID: NCT05481112 Withdrawn - Opioid Use Disorder Clinical Trials

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Start date: November 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this study is to compare two approaches for commencing pharmacotherapy with injectable buprenorphine for opioid use disorder (OUD) among jail inmates: (1) at the time of admission or (2) shortly before release. A sample of eligible inmates with sentences of less than 180 days will be randomly assigned to (1) initiating extended-release buprenorphine (XR-B) treatment at the time of admission (n=80), or (2) initiating XR-B treatment within 30 prior to their scheduled release date (n=80). The groups will be compared with regard to (1) how likely they were to participate in treatment, (2) levels of in-jail opioid use (via post-release interviews), (3) continuation of pharmacotherapy and other OUD treatment in the community, and (4) levels of opioid use 4 and 12 weeks following discharge (self-report and incentivized voluntary urine tests).

NCT ID: NCT05480657 Withdrawn - Clinical trials for Brittle Type 1 Diabetes Mellitus

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

Start date: September 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.

NCT ID: NCT05474352 Withdrawn - Clinical trials for Hyperthermic Intraperitoneal

Use of Water Warming/Cooling Garment to Maintain a Constant Intraoperative Core Target Temperature in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Proof-of-Concept Study

Start date: June 14, 2022
Phase: Early Phase 1
Study type: Interventional

To look at the feasibility of using a water warming/cooling garment (called the ALLON system) to maintain a target body temperature during surgery and chemotherapy perfusion (a method of pouring chemotherapy throughout your abdominal cavity) without overheating or overcooling your body.

NCT ID: NCT05472506 Withdrawn - Clinical trials for Head and Neck Cancer

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Start date: March 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1b study in adult patients diagnosed with resistant or recurrent head and neck squamous cell carcinoma (HNSCC) designed to assess the safety and tolerability of IK-175 in combination with nivolumab. Disease response, pharmacokinetics (PK), pharmacodynamics, and response biomarkers will also be assessed.

NCT ID: NCT05472077 Withdrawn - COVID-19 Clinical Trials

Lollipop COVID-19 Testing Study

Start date: July 2023
Phase: N/A
Study type: Interventional

This study will explore whether lollipop swabs are more acceptable and perform as well as nasal swabs with PCR testing. The study will be open to enrollment for both children and adults in the Madison community who have at least one COVID-19 symptom that has presented in the last 5 days and who have not had a positive COVID-19 test for a previous illness within the past 3 months. Participants can expect to be in the study for the duration of the swabbing, approximately 10 minutes.

NCT ID: NCT05469802 Withdrawn - Healthy Volunteers Clinical Trials

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Start date: January 2, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to describe the side effects and immune response of a candidate vaccine that might protect against Zika. The vaccine called PIZV (purified inactivated Zika virus vaccine) is given by injection in two doses that are 28 days apart in healthy adults. Participants will receive PIZV or placebo and will be followed for 7 days after each dose and up to 6 months after dose 2.

NCT ID: NCT05467761 Withdrawn - Healthy Clinical Trials

Bioavailability Study of Psilocybin in Normal Adults

Start date: June 2023
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to compare an oral dose of psilocybin and an intravenous (IV) infusion of psilocybin to assess differences in how the drug is absorbed by the body, the psychedelic experience, and any side effects when taken by healthy adult participants. Participants can expect to be in the study for approximately 12 weeks.

NCT ID: NCT05466916 Withdrawn - Gynecologic Cancer Clinical Trials

EDITS Pilot Study for Gynecologic Cancer Survivors

Start date: July 20, 2022
Phase: N/A
Study type: Interventional

The main goal in this project is to develop and pilot test a 12-week multiple health behavior change (MHBC) intervention for feasibility and acceptability. The pilot study will be guided by Multiphase Optimization Strategy (MOST) framework, which uses highly efficient experiments to systematically test and compare intervention components' or component levels' individual and combined effects. The goal of the MOST framework is to balance effectiveness with affordability, sustainability, and efficiency.